- Patients with coronary artery disease who were high-dose statin intolerant, dual combination therapy with low-dose statin (LDS) and either ezetimibe or nutraceuticals is a reliable, effective and a safe treatment option.
Why this matters
- European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines for dyslipidaemia management recommend use of nutraceuticals as an alternative or additional lipid-lowering drug.
- TACO evaluated 100 high-dose statin-intolerant patients with coronary artery disease who underwent percutaneous coronary intervention in the preceding 12 months and were not at low-density lipoprotein cholesterol (LDL-C) target (
- Patients were randomly allocated to receive either LDS+ezetimibe or LDS+nutraceuticals (Armolipid Plus containing red yeast rice, policosanol, and berberine [Armolipid+]) for 3 months.
- Patients not achieving therapeutic goal received triple combination therapy of LDS+ezetimibe+Armolipid+ for further 3 months.
- Funding: Italian Ministry of Education.
- 66% vs 62% patients who received LDS+ezetimibe and LDS+Armolipid+, respectively, achieved LDL-C therapeutic target at 3 months and maintained it at 6 months.
- Reduction in LDL-C concentration at 3 months was higher in LDS+Armolipid+ (–26 mg/dL) vs LDS+ezetimibe (–16 mg/dL) group (P<.00001>
- Reduction in total cholesterol was significantly greater in LDS+Armolipid+ vs LDS+ezetimibe group (P=.0005).
- 78% of patients receiving triple therapy achieved therapeutic target.
- None of the patients experienced major side effects.
- Small study population.